Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor
Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor
复制标题
使用新型肿瘤来源细胞系进行药物筛选，为非典型畸胎瘤/横纹肌样瘤患者确定了替代治疗选择
DOI：
10.1007/s13577-020-00438-3
复制
发表时间：
2020
期刊：
影响因子：
4.3
通讯作者：
Ichimura Koichi
中科院分区：
文献类型：
--
作者：
Nakano Yoshiko;Takadera Mutsumi;Miyazaki Makoto;Qiao Zhiwei;Nakajima Kosei;Noguchi Rei;Oyama Rieko;Kimura Yui;Okuhiro Yuki;Yamasaki Kai;Kunihiro Noritsugu;Fukushima Hiroko;Inoue Takeshi;Hara Junichi;Ozawa Tatsuya;Kondo Tadashi;Ichimura Koichi
非典型畸胎瘤/横纹肌样瘤是一种罕见的颅内肿瘤，主要发生在幼儿。预后很差，目前没有有效的治疗方法。为了开发新的有效治疗方法，需要建立AT/RT的实验模型。在这项研究中，我们从患者的AT/RT组织（指定ATRT_OCGH）中建立了细胞系，并使用164种fda批准的抗癌药物进行药物筛选，以确定治疗方案的候选药物。我们发现，与酪氨酸激酶抑制剂、拓扑异构酶抑制剂和组蛋白去乙酰化酶抑制剂一样，蛋白酶体抑制剂硼替佐米是细胞系表现出高敏感性的药物之一，这些药物已知具有抗at /RT作用。同时使用帕比司他可增强硼替佐米对AT/RT细胞增殖的抑制作用。我们的研究结果可能为考虑帕比司他和硼替佐米联合治疗AT/RT提供理论依据。
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare intracranial tumor occurring predominantly in young children. The prognosis is poor, and no effective treatment is currently available. To develop novel effective therapies, there is a need for experimental models for AT/RT. In this research, we established a cell line from a patient’s AT/RT tissue (designated ATRT_OCGH) and performed drug screening using 164 FDA-approved anti-cancer agents, to identify candidates for therapeutic options. We found that bortezomib, a proteasome inhibitor, was among the agents for which the cell line showed high sensitivity, along with tyrosine kinase inhibitors, topoisomerase inhibitors, and histone deacetylase inhibitors, which are known to exert anti-AT/RT effects. Concomitant use of panobinostat potentiated the inhibitory effect of bortezomib on AT/RT cell proliferation. Our findings may provide a rationale for considering combination therapy of panobinostat and bortezomib for treatment of AT/RT.
登录
查看更多内容
影响因子：
50.3
作者：
Carugo A;Minelli R;Sapio L;Soeung M;Carbone F;Robinson FS;Tepper J;Chen Z;Lovisa S;Svelto M;Amin S;Srinivasan S;Del Poggetto E;Loponte S;Puca F;Dey P;Malouf GG;Su X;Li L;Lopez-Terrada D;Rakheja D;Lazar AJ;Netto GJ;Rao P;Sgambato A;Maitra A;Tripathi DN;Walker CL;Karam JA;Heffernan TP;Viale A;Roberts CWM;Msaouel P;Tannir NM;Draetta GF;Genovese G
通讯作者：
Genovese G
影响因子：
50.3
作者：
Johann, Pascal D.;Erkek, Serap;Kool, Marcel
通讯作者：
Kool, Marcel
影响因子：
15.9
作者：
Fruehwald, Michael C.;Biegel, Jaclyn A.;Chi, Susan N.
通讯作者：
Chi, Susan N.
从播散性脑脊液细胞中建立非典型畸胎瘤/横纹肌样瘤（AT/RT）细胞培养物：阐明生物学和潜在靶向治疗的模型
影响因子：
3.9
作者：
A. Narendran;Lucas Coppes;Aarthi Jayanthan;Michael Coppes;B. Teja;D. Bernoux;David George;D. Strother
通讯作者：
D. Strother
影响因子：
11.2
作者：
Schewe DM;Aguirre-Ghiso JA
通讯作者：
Aguirre-Ghiso JA